ResApp deal dips on test results

21/06/2022 - 11:47

Bookmark

Save articles for future reference.

Pfizer takeover target ResApp has had its valuation cut after its COVID-19 detecting cough tool failed to meet performance requirements needed to lock in an improved all-cash offer for the business.

Subscribe to read this article.

Register or login now and receive unlimited access to our award-winning, unbiased and trusted
journalism. Your key to local business, news, insights and data.

Subscribe today for award-winning, unbiased and trusted journalism

Subscription Options